The FDA has granted fast track designation to Annexon Biosciences' ANX005, an investigational treatment for Guillain-Barré syndrome. A Phase Ib trial has been completed and the sponsor will conduct later stage clinical trials. Guillian- Barré syndrome Guillian-...